Daniel Holder

6.4k total citations · 2 hit papers
74 papers, 4.4k citations indexed

About

Daniel Holder is a scholar working on Molecular Biology, Statistics and Probability and Physiology. According to data from OpenAlex, Daniel Holder has authored 74 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Statistics and Probability and 9 papers in Physiology. Recurrent topics in Daniel Holder's work include Statistical Methods in Clinical Trials (10 papers), HIV Research and Treatment (6 papers) and Molecular Biology Techniques and Applications (5 papers). Daniel Holder is often cited by papers focused on Statistical Methods in Clinical Trials (10 papers), HIV Research and Treatment (6 papers) and Molecular Biology Techniques and Applications (5 papers). Daniel Holder collaborates with scholars based in United States, Germany and United Kingdom. Daniel Holder's co-authors include Jon H. Condra, Anne R. Meibohm, Emilio A. Emini, William A. Schleif, Deborah K. McMahon, Douglas D. Richman, Leslie Jonas, Jeffrey Chodakewitz, Roy M. Gulick and Joseph J. Eron and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Daniel Holder

69 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

1997 1.5k citations Daniel Holder, Jon H. Condra et al. profile →
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

2010 520 citations Vishal S. Vaidya, Josef Ozer et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Holder United States	29	1.6k	1.5k	1.0k	532	476	74	4.4k
David Barnett United Kingdom	38	411 0.3×	517 0.3×	1.4k 1.4×	421 0.8×	367 0.8×	134	4.3k
William Lewis United States	44	1.9k 1.2×	1.2k 0.8×	2.4k 2.3×	1.3k 2.5×	682 1.4×	111	6.8k
Judy K. Shigenaga United States	40	544 0.3×	353 0.2×	2.0k 1.9×	1.3k 2.5×	748 1.6×	65	5.8k
Ignacio Conget Spain	35	629 0.4×	499 0.3×	626 0.6×	369 0.7×	401 0.8×	213	4.8k
David Nolan Australia	41	2.1k 1.3×	1.9k 1.3×	804 0.8×	940 1.8×	675 1.4×	149	7.3k
Gennaro Galasso Italy	37	490 0.3×	200 0.1×	1.0k 1.0×	811 1.5×	333 0.7×	218	4.6k
Cyril Mamotte Australia	26	302 0.2×	225 0.2×	798 0.8×	298 0.6×	548 1.2×	67	3.4k
Julie A. Stone United States	36	1.7k 1.0×	521 0.3×	515 0.5×	735 1.4×	206 0.4×	88	3.3k
Lorraine C. Racusen United States	58	633 0.4×	135 0.1×	1.7k 1.7×	758 1.4×	543 1.1×	160	9.5k
Avi Z. Rosenberg United States	37	802 0.5×	51 0.0×	2.4k 2.3×	761 1.4×	266 0.6×	163	5.8k

Countries citing papers authored by Daniel Holder

Since Specialization

Citations

This map shows the geographic impact of Daniel Holder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Holder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Holder more than expected).

Fields of papers citing papers by Daniel Holder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Holder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Holder. The network helps show where Daniel Holder may publish in the future.

Co-authorship network of co-authors of Daniel Holder

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Holder. A scholar is included among the top collaborators of Daniel Holder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Holder. Daniel Holder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holder, Daniel, et al.. (2025). Combining additive and subtractive laser processing to produce small holes and narrow grooves of unlimited depth. Optics & Laser Technology. 192. 113443–113443. 1 indexed citations

Villarreal, Stephanie, Fuqiang Zhao, Lynn A. Hyde, et al.. (2017). Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. Journal of Alzheimer s Disease. 59(4). 1393–1413. 22 indexed citations

Burch, Peter M., Warren E. Glaab, Daniel Holder, et al.. (2016). Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance. Toxicological Sciences. 156(1). kfw225–kfw225. 23 indexed citations

Öhrfelt, Annika, Ulf Andréasson, Adam J. Simon, et al.. (2011). Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders Extra. 1(1). 31–42. 32 indexed citations

Vaidya, Vishal S., Josef Ozer, Frank Dieterle, et al.. (2010). Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology. 28(5). 478–485. 520 indexed citations breakdown →

Yu, Yan, Hong Jin, Daniel Holder, et al.. (2010). Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnology. 28(5). 470–477. 147 indexed citations

Zhang, Xiaohua Douglas, Raul Lacson, Ruojing Yang, et al.. (2010). The Use of SSMD-Based False Discovery and False Nondiscovery Rates in Genome-Scale RNAi Screens. SLAS DISCOVERY. 15(9). 1123–1131. 21 indexed citations

Gentile, Michael A., Pascale V. Nantermet, Robert L. Vogel, et al.. (2009). Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of β-catenin. Journal of Molecular Endocrinology. 44(1). 55–73. 59 indexed citations

Nantermet, Pascale V., Shun-ichi Harada, Yuan Liu, et al.. (2008). Gene Expression Analyses in Cynomolgus Monkeys Provides Mechanistic Insight into High-Density Lipoprotein-Cholesterol Reduction by Androgens in Primates. Endocrinology. 149(4). 1551–1561. 10 indexed citations

10.

Webber, Andrea L., Paul Hodor, Catherine J. Thut, et al.. (2008). Dual role of Nr2e3 in photoreceptor development and maintenance. Experimental Eye Research. 87(1). 35–48. 38 indexed citations

11.

Zhang, Xiaohua Douglas, Marc Ferrer, Amy S. Espeseth, et al.. (2007). The Use of Strictly Standardized Mean Difference for Hit Selection in Primary RNA Interference High-Throughput Screening Experiments. SLAS DISCOVERY. 12(4). 497–509. 74 indexed citations

12.

Jiang, Ying, David Gerhold, Daniel Holder, et al.. (2007). Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles. Journal of Translational Medicine. 5(1). 47–47. 15 indexed citations

13.

Brandish, Philip E., Daniel Holder, Paul Hodor, et al.. (2005). Regulation of Gene Expression by Lithium and Depletion of Inositol in Slices of Adult Rat Cortex. Neuron. 45(6). 861–872. 69 indexed citations

14.

Nantermet, Pascale V., Jian Xu, Paul Hodor, et al.. (2004). Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland. Journal of Biological Chemistry. 279(2). 1310–1322. 96 indexed citations

15.

Saah, Alfred J., David W. Haas, Mark J. DiNubile, et al.. (2003). Treatment with Indinavir, Efavirenz, and Adefovir after Failure of Nelfinavir Therapy. The Journal of Infectious Diseases. 187(7). 1157–1162. 11 indexed citations

16.

Holder, Daniel, et al.. (2001). Statistical analysis of high density oligonucleotide arrays: a SAFER approach. 13 indexed citations

17.

Grupp, Ingrid L., Daniel Holder, Albrecht Schmidt, et al.. (2001). The Enhanced Contractility of the Phospholamban-deficient Mouse Heart Persists with Aging. Journal of Molecular and Cellular Cardiology. 33(5). 1031–1040. 55 indexed citations

18.

Holder, Daniel, et al.. (1995). Evaluation of lymphocyte proliferation by immunohistochemistry in the local lymph node assay. Journal of Applied Toxicology. 15(6). 465–475. 20 indexed citations

19.

Gunning, Frans P., A Béchetoille, Erik A. Lippa, et al.. (1992). Sezolamide: Additivity to timolol twice daily. Eye. 6(5). 525–529. 4 indexed citations

20.

Lippa, Erik A., Joel S. Schuman, Eve J. Higginbotham, et al.. (1991). MK-507 versus Sezolamide. Ophthalmology. 98(3). 308–313. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact